
Louisville, KY-Potentia Pharmaceuticals Inc. and University of Pennsylvania entered into an exclusive, worldwide licensing agreement that allows Potentia to develop and commercialize the university's Compstatin class of complement-inhibiting peptides for the treatment of ocular diseases. The agreement allows Potentia to move forward with preclinical development of the first complement-inhibiting drug product aimed at treating both wet and dry forms of age-related macular degeneration.
